Please confirm you are human (Sign Up for free to never see this)
← Back to Search
KRAS Mutant Pancreatic Cancer: No Lone Path To An Effective Treatment
Daniel Zeitouni, Y. Pylayeva-Gupta, C. Der, K. L. Bryant
Published 2016 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers with a dismal 7% 5-year survival rate and is projected to become the second leading cause of cancer-related deaths by 2020. KRAS is mutated in 95% of PDACs and is a well-validated driver of PDAC growth and maintenance. However, despite comprehensive efforts, an effective anti-RAS drug has yet to reach the clinic. Different paths to inhibiting RAS signaling are currently under investigation in the hope of finding a successful treatment. Recently, direct RAS binding molecules have been discovered, challenging the perception that RAS is an “undruggable” protein. Other strategies currently being pursued take an indirect approach, targeting proteins that facilitate RAS membrane association or downstream effector signaling. Unbiased genetic screens have identified synthetic lethal interactors of mutant RAS. Most recently, metabolic targets in pathways related to glycolytic signaling, glutamine utilization, autophagy, and macropinocytosis are also being explored. Harnessing the patient’s immune system to fight their cancer is an additional exciting route that is being considered. The “best” path to inhibiting KRAS has yet to be determined, with each having promise as well as potential pitfalls. We will summarize the state-of-the-art for each direction, focusing on efforts directed toward the development of therapeutics for pancreatic cancer patients with mutated KRAS.
This paper references
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
C. Scholl (2009)
Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance
C. Lyssiotis (2013)
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia.
M. Kanda (2012)
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
G. Zimmermann (2013)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
J. Engelman (2009)
Scanning the horizon for focused interventions
KRAS: feeding pancreatic cancer proliferation.
Kirsten L Bryant (2014)
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
S. Cohen (2003)
Mutant KRAS is a druggable target for pancreatic cancer
Elina Zorde Khvalevsky (2013)
Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers
J. Engelman (2008)
Glutamine and cancer: cell biology, physiology, and clinical opportunities.
Christopher T. Hensley (2013)
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
M. Steckel (2012)
Stable suppression of tumorigenicity by virus-mediated RNA interference.
T. Brummelkamp (2002)
Targeting RAS-mutant cancers: is ERK the key?
Meagan B. Ryan (2015)
Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen.
S. Morgan-Lappe (2007)
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
M. V. Van Dort (2015)
p53 status determines the role of autophagy in pancreatic tumour development
M. Rosenfeldt (2013)
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.
T. Hayes (2016)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
J. Duncan (2012)
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
P. Provenzano (2012)
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
E. Morris (2013)
ERK1/2 MAP kinases: structure, function, and regulation.
R. Roskoski (2012)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman (2009)
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
E. Van Cutsem (2004)
Dragging ras back in the ring.
A. Stephen (2014)
Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor
E. Meuillet (2010)
Hyaluronan: its nature, distribution, functions and turnover
J. E. Fraser (1997)
A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.
E. Collisson (2012)
The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1
Wilhelm Palm (2015)
Small RNA combination therapy for lung cancer
W. Xue (2014)
B. Bynum (2015)
Changing the course of pancreatic cancer--Focus on recent translational advances.
M. Javle (2016)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
J. Wilmott (2011)
Autophagy mediates the mitotic senescence transition.
A. Young (2009)
BRAF inhibition improves tumor recognition by the immune system
M. Donia (2012)
Pancreatic cancer: Scanning the horizon for focused interventions
J L Abbruzzese
H. Kocher (2010)
Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
R. Mohammad (1999)
Cancer statistics, 2016
R. Siegel (2016)
Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.
Kian-Huat Lim (2005)
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
A. Le (2010)
Lipid posttranslational modifications. Farnesyl transferase inhibitors.
A. Basso (2006)
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation.
Jian-Bin Wang (2010)
Phase 1b Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
S. R. Hingorani (2016)
The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins
Anchal Chandra (2012)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
G. Hatzivassiliou (2010)
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.
Y. Ko (2004)
RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
P. Poulikakos (2010)
Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation.
Q. Sun (2012)
Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy
C. Eng (2015)
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
D. Barbie (2009)
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
M. Schutte (1997)
Development of siRNA payloads to target KRAS-mutant cancer.
T. Yuan (2014)
Down‐regulation of the MHC class I antigen‐processing machinery after oncogenic transformation of murine fibroblasts
B. Seliger (1998)
Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors
Pamela J Sung (2013)
Pancreatic cancer: Scanning the horizon for focused interventions Available online: http://deainfo.nci.nih.gov/advisory/ctac/archive/0313/PCwgReport
J L Abbruzzese (2016)
Cancer statistics, 2016
Rebecca L. Siegel Mph (2016)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
S. Heidorn (2010)
Targeting RAS–ERK signalling in cancer: promises and challenges
A. Samatar (2014)
Glutamine addiction: a new therapeutic target in cancer.
D. Wise (2010)
Marine organisms as a source of new anticancer agents.
G. Schwartsmann (2001)
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
C. Liu (2012)
Exploiting the bad eating habits of Ras-driven cancers.
E. White (2013)
Dacarbazine-induced immunogenicity of a murine leukemia is attenuated in cells transfected with mutated K-ras gene.
C. Testorelli (1997)
Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer.
K. C. Patra (2013)
Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors Published, JLR Papers in Press, November 8, 2005.
A. Basso (2006)
Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer
M. Junttila (2014)
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
M. Burns (2014)
A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside
Y. H. Ko (2012)
Molecular Consequences of Silencing Mutant K-ras in Pancreatic Cancer Cells: Justification for K-ras–Directed Therapy
J. Fleming (2005)
Genome-Wide Somatic Copy Number Alterations in Low-Grade PanINs and IPMNs from Individuals with a Family History of Pancreatic Cancer
S. Hong (2012)
Recent progress in pancreatic cancer
C. Wolfgang (2013)
et al. Mutant KRAS is a druggable target for pancreatic cancer
Two sides of the story? Smad4 loss in pancreatic cancer versus head‐and‐neck cancer
S. Malkoski (2012)
Improved Treatment of Pancreatic Cancer With Drug Delivery Nanoparticles Loaded With a Novel AKT/PDK1 Inhibitor
Joseph E. Kobes (2016)
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
T. Golan (2015)
Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells.
W. Zhou (2012)
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group
J S Macdonald (2005)
Inflammatory networks and immune surveillance of pancreatic carcinoma.
R. Vonderheide (2013)
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
T. Maurer (2012)
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
M. Kumar (2012)
Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth.
C. Barceló (2014)
The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.
K. Scheffzek (1997)
Marine natural products: Bryostatins in preclinical and clinical studies
P. Kollar (2014)
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability
Tuoping Luo (2012)
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis.
J. Guo (2011)
Cancer-associated stromal fibroblasts promote pancreatic tumor progression.
R. Hwang (2008)
Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
S Loi (2016)
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
L. Rahib (2014)
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
G. Hatzivassiliou (2013)
Feeding pancreatic cancer proliferation
K L Bryant (2014)
Hallmarks of Cancer: The Next Generation
D. Hanahan (2011)
Inhibitors of the Ras superfamily of small G-proteins. Preface.
F. Tamanoi (2013)
Trametinib: a MEK inhibitor for management of metastatic melanoma
I. Lugowska (2015)
W. Schima (2006)
Autophagy and Metabolism
J. Schneider (2016)
Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents.
R. Mohammad (1998)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*
C. Thoreen (2009)
Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3
Asli Muvaffak (2014)
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
H. Ying (2012)
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
J. Luo (2009)
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
S. Hingorani (2016)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
A. Biankin (2012)
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.
Y. Pylayeva-Gupta (2012)
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
C. Britten (2013)
A central role for RAFÑMEKÑERK signaling in the genesis of pancreatic ductal adenocarcinoma
E. A. Collisson (2012)
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin
K. Delp (2000)
Pancreatic cancers require autophagy for tumor growth.
Shenghong Yang (2011)
Autophagy in cancer: good, bad, or both?
Melanie M Hippert (2006)
A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
G. Riely (2011)
Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway
Jaekyoung Son (2013)
Cancer statistics CA Cancer J. Clin
R L Siegel (2016)
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies
X. Wang (2015)
Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein.
J. Kamphorst (2015)
The mTORC1/S6K1 Pathway Regulates Glutamine Metabolism through the eIF4B-Dependent Control of c-Myc Translation
Alfredo Csibi (2014)
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
A. Cox (2015)
In Vivo RNAi Screening Identifies Regulators of Actin Dynamics as Key Determinants of Lymphoma Progression
Corbin E. Meacham (2009)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell (2015)
Selective Inhibition of Ras-dependent Cell Growth by Farnesylthiosalisylic Acid (*)
M. Marom (1995)
The pre-hydrolysis state of p21(ras) in complex with GTP: new insights into the role of water molecules in the GTP hydrolysis reaction of ras-like proteins.
A. Scheidig (1999)
et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer
M S Kumar (2012)
Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES).
M. Robinson (2007)
Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs
C. Pecot (2014)
Targeting protein prenylation for cancer therapy
Norbert Berndt (2011)
Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations.
Annan Yang (2014)
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.
Meredith A. Collins (2012)
ZSTK474 is an ATP‐competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms
Dexin Kong (2007)
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
A. Witkiewicz (2015)
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
S. Peng (2015)
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
C. García-Echeverría (2008)
N. Engl. J. Med
D P Ryan (2014)
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
L. Liu (2015)
Metabolism and action of amino acid analog anti-cancer agents.
G. Ahluwalia (1990)
Regulating the regulator: post-translational modification of RAS
Ian Ahearn (2011)
A High-Throughput Soft Agar Assay for Identification of Anticancer Compound
S. N. Anderson (2007)
A. Cox (2010)
Dislodgment and accelerated degradation of ras
Y. Kloog (1997)
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Cosimo Commisso (2013)
PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis.
T. Bivona (2006)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
J. Ostrem (2013)
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study
J. Macdonald (2005)
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
A. Gilmartin (2011)
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis.
A. Sparmann (2004)
Mol. Cancer Ther
Only women with symptoms need to have their breast implants removed, says government
Bond-Smith Giles (2012)
Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma.
Alexander P Stark (2015)
PI3K and cancer: lessons, challenges and opportunities
D. Fruman (2014)
Inhibitors of chronically active ras: potential for treatment of human malignancies.
R. Blum (2008)
Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.
S. Eser (2013)
Multiple Levels of MHC Class I Down‐Regulation by ras Oncogenes
S. Lohmann (1996)
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
S. Loi (2015)
RAF inhibitors that evade paradoxical MAPK pathway activation
C. Zhang (2015)
Molecular pharmacology and antitumor activity
E J Meuillet
Autophagy and metabolism Autophagy in cancer: Good, bad, or both? Cancer Res
J D Rabinowitz (2006)
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
D. Vigil (2010)
Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells
A. Sarthy (2007)
K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
Frederick D. Tsai (2015)
A comprehensive survey of Ras mutations in cancer.
I. Prior (2012)
Reduced stimulation of helper T cells by Ki-ras transformed cells.
D. Maudsley (1991)
Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma.
B. M. Wolpin (2014)
Ras/MAPK signaling from endomembranes
Nicole Fehrenbacher (2009)
Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
B. Seliger (1996)
In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras–effector interaction
F. Shima (2013)
Drugging the undruggable RAS: Mission Possible?
A. Cox (2014)
Understanding the stroma of pancreatic cancer: co‐evolution of the microenvironment with epithelial carcinogenesis
M. Erkan (2013)
Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome
S. Fujii (2008)
Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes
R. Kadaba (2013)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
R. Royal (2010)
StellaTUM: current consensus and discussion on pancreatic stellate cell research
M. Erkan (2011)
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
S. Jones (2008)
N. Dubrawsky (1989)
Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
R. Seifert (2013)
Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.
S. M. Lim (2014)
Inhibition of Ras for cancer treatment: the search continues.
A. Baines (2011)
The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions
Seunghee Yoon (2006)
Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival.
M. Elgendy (2011)
This paper is referenced by
EGFR and KRAS mutations in Chinese patients with sinonasal inverted papilloma and oncocytic papilloma
H. Wang (2019)
Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice
K. Hedegger (2020)
The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis
Rongyuan Zhuang (2017)
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
L. Buscail (2020)
PDAC-ANN: an artificial neural network to predict Pancreatic Ductal Adenocarcinoma based on gene expression
Palloma Porto Almeida (2019)
Serotonin uptake is required for Rac1 activation in Kras‐induced acinar‐to‐ductal metaplasia in the pancreas
Enrica Saponara (2018)
Mechanical-control of cell proliferation increases resistance to chemotherapeutic agents
I. Rizzuti (2020)
Oxidative Stress and Gastrointestinal System Cancers
Ahmet Engin Atay (2017)
Macropinocytosis Exploitation by Cancers and Cancer Therapeutics
K. Ha (2016)
A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model
S. Park (2018)
Defeat mutant KRAS with synthetic lethality
X. Pang (2017)
Functionalized Graphene@Gold Nanostar/Lipid for Pancreatic Cancer Gene and Photothermal Synergistic Therapy under Photoacoustic/Photothermal Imaging Dual-Modal Guidance.
Xiuna Jia (2020)
Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Yifan Zhang (2019)
Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality
T. Donahue (2016)
Proteogenomic Network Analysis of Context-Specific KRAS Signaling in Mouse-to-Human Cross-Species Translation.
Douglas K. Brubaker (2019)
Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis
Pyone Myat Thu (2019)
Overhang molecular beacons encapsulated in tethered cationic lipoplex nanoparticles for detection of single-point mutation in extracellular vesicle-associated RNAs.
Jiaming Hu (2018)
Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer
J. Zhang (2018)
KRAS as Potential Target in Colorectal Cancer Therapy
Shu-Kee Eng (2019)
Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment
J. Mahmood (2018)
БИОМАРКЕРЫ, НЕОАНГИОГЕНЕЗ И ФАКТОРЫ РОСТА ПРИ РАКЕ ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ
Е. М. Франциянц (2019)
Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes
Jia-Ren Lin (2018)
The Yeast Saccharomyces cerevisiae as a Model for Understanding RAS Proteins and Their Role in Human Tumorigenesis
Giulia Cazzanelli (2018)
Molecular subtypes of pancreatic adenocarcinoma
Jacob S. Bowers (2019)
Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models
Chrysovalantou Mihailidou (2018)
Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP
A. Lev (2017)
Mutation-specific and common phosphotyrosine signatures of KRAS G12D and G13D alleles.
Raiha Tahir (2020)
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules
M. Gatti-Mays (2019)
PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KIIα, Inhibits the Growth of Breast Cancer Cells.
Jiangmei Li (2017)
Overview of Current Immunotherapies Targeting Mutated KRAS Cancers.
W. Hoo (2019)
The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers
H. A. Mokhlis (2019)
Selective targeting of an oncogenic KRAS mutant allele by CRISPR/Cas9 induces efficient tumor regression
Qianqian Gao (2019)See more